Jasmine Zain, MD
Hematology · Duarte, CANPI 1043327075
Payments from drug & device makers
Across 257 payments — averaging $8327.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$657K
- AbbVie$469K
- Astrazeneca UK Limited$286K
- Secura Bio, Inc.$261K
- Seagen Inc.$132K
- Merck$72K
- plus $263K from 17 others
Across 1 payment — averaging $650.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Beigene, Ltd.$650
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Inc. | 61 | $657,111 |
| AbbVie | 11 | $468,993 |
| Astrazeneca UK Limited | 6 | $285,799 |
| Secura Bio, Inc. | 24 | $260,924 |
| Seagen Inc. | 60 | $132,234 |
| Merck | 11 | $72,406 |
| Taiho Oncology, Inc. | 4 | $58,892 |
| Pfizer | 4 | $58,523 |
| ADC Therapeutics America, Inc. | 6 | $50,724 |
| Y-mabs Therapeutics, Inc. | 11 | $37,500 |
| Kyowa Kirin, Inc. | 32 | $33,423 |
| Kyowa Kirin Services Ltd | 8 | $15,313 |
| Acrotech Biopharma Inc. | 3 | $4,659 |
| Verastem, Inc. | 3 | $2,833 |
| Genmab U.S., Inc. | 2 | $213 |
| Morphosys, US Inc. | 1 | $138 |
| Helsinn Therapeutics (U.S.), Inc. | 4 | $120 |
| Gilead | 1 | $120 |
| Genentech USA, Inc. | 1 | $79 |
| Beigene USA, Inc. | 1 | $62 |
| Jazz Pharmaceuticals Inc. | 1 | $25 |
| Johnson & Johnson | 1 | $20 |
| Amgen | 1 | $19 |
How this compares
$2,140,128 in reported general payments places this provider in the 75th percentile of 178 hematology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology in Duarte
- Alex HerreraDuarte$50.9M
- Tycel PhillipsDuarte$21.6M
- Lihua BuddeDuarte$21.5M
- Tanya SiddiqiDuarte$18.8M
- Amrita KrishnanDuarte$14M
- Anthony SteinDuarte$12.1M
- Alexey DanilovDuarte$11.3M
- Vincent ChungDuarte$11.1M
- Vinod PullarkatDuarte$10M
- Ibrahim AldossDuarte$9.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.